Tessa’s story started over 30 years ago, when Dr. Malcolm Brenner, our co-founder, and his team at Baylor College of Medicine embarked on a journey to better understand and harness the body’s natural anti-viral immune response as a therapy for cancer treatment. Their research has led to several clinical studies investigating the use of a type of immune cells, known as Virus-Specific T cells (VSTs) against cancer. These studies have shown early efficacy and a strong safety profile in cancer patients.
Leveraging these promising data, Tessa initiated a Phase II clinical trial for TT10, a VST therapy targeting nasopharyngeal cancer (NPC), at National Cancer Centre Singapore (NCCS), which produced the best published 2-year survival data in patients with advanced NPC. The trial results set the stage for a Phase III trial — the world’s largest T cell therapy trial for any cancer indication with 330 patients across 30 hospitals in 5 countries .
Today, Tessa is building a portfolio of next-generation cell therapies targeting a wide range of cancer indications. We are proud to be innovators in the field of cancer immunotherapy, and are committed to making a difference in the lives of cancer patients worldwide.
Leveraging the non-alloreactive properties and safety profile of VSTs, Tessa is building a new integrated platform technology that holds potential to be applied in an allogeneic setting against a broad range of cancers, including solid tumors.
At the core of this platform, Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-Chimeric Antigen Receptor (CAR) technology to increase efficacy. Encouraging preclinical and early clinical data demonstrate the promise of this scientific approach.
We have a fast-growing pipeline of autologous and allogeneic therapies that include two late-stage clinical studies targeting Hodgkin lymphoma and nasopharyngeal cancer.
A Multi-Country, Multi-Site Production and Supply Chain Network
Building robust, scalable operational capabilities is a critical aspect of our strategy to promptly and reliably deliver cell therapies to patients worldwide.
Bolstered by a global production and supply chain footprint, and a strong clinical trial network, our cell therapies are currently delivered to patients in 30 clinical sites across 5 countries. To date, Tessa has successfully delivered over 150 autologous cell therapies in a Phase III clinical trial setting.
Tessa plans to open a 90,000 square foot commercial-scale cell therapy manufacturing facility in Singapore by end-2020, which will be one of the leading of its kind in Asia. The state-of-the-art facility will enable us to deliver our cell therapies faster and more reliably, to thousands of cancer patients annually worldwide. It will run both clinical and commercial manufacturing of cell therapy products that are compliant with current Good-Manufacturing-Practice (cGMP) guidelines from the U.S. Food and Drug Administration, European Medicines Agency and key regulators in Asia.
Read more about our upcoming facility here.
A Global Clinical Trial Network for Accelerated Trial Roll-outs
Together with our academic, clinical, and scientific research partners, Tessa has established a fully integrated approach to the treatment of cancer with immunotherapy.
Our clinical trial partners include leading institutions in the United States, such as the Stanford Cancer Institute, City of Hope National Medical Center, UCSF Medical Center, Baylor College of Medicine, Baylor Scott & White Health, as well as other Centers of Excellence in Massachusetts, Texas, and California.